Valuation: Rhelion Life Sciences Corp.

Market Cap 15.35M 10.87M 9.69M 8.96M 8.16M 1.03B 15.61M 108M 42.36M 539M 40.79M 39.91M 1.72B P/E 2025
-2.98x
P/E 2026 -1.71x
Enterprise Value 7.12M 5.04M 4.49M 4.15M 3.78M 479M 7.24M 50.18M 19.64M 250M 18.92M 18.51M 796M EV / Sales 2025
0.29x
EV / Sales 2026 0.57x
Free-Float
94.46%
Yield 2025 *
-
Yield 2026 -
Current month-16.67%
1 month-23.08%
3 months-16.67%
6 months-16.67%
Current year+25.00%
1 week 0.02
Extreme 0.02
0.03
1 month 0.02
Extreme 0.02
0.04
Current year 0.02
Extreme 0.015
0.05
1 year 0.02
Extreme 0.015
0.05
3 years 0.02
Extreme 0.015
0.08
5 years 0.02
Extreme 0.015
0.22
10 years 0.02
Extreme 0.015
0.7
Manager TitleAgeSince
Chief Executive Officer - 2020-05-21
Director of Finance/CFO - 2026-08-18
President 40 -
Director TitleAgeSince
Chairman - 1982-09-28
Chairman - 2020-05-24
Director/Board Member 31 2019-02-28
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-28.57%-64.29% 10.85M
-1.58%-1.33%+17.56%+39.99% 48.17B
+3.40%-0.05%-18.81%+14.84% 34.52B
+3.46%+2.35%-17.92%-13.65% 15.17B
-0.92%+0.51%-29.53%-3.35% 10.57B
+0.47%+0.94%-1.83%+12.04% 5.23B
-1.21%-2.98%-20.17%+328.70% 4.6B
+1.98%-2.33%-30.68%-35.79% 4.49B
+1.79%-2.06%-3.72%+3.64% 3.92B
+0.84%+0.61%-10.36%+0.99% 3.52B
Average +0.82%-0.74%-14.40%+28.31% 13.02B
Weighted average by Cap. +0.77%-1.16%-5.21%+27.87%

Financials

2025 2026
Net sales 4.94M 3.5M 3.12M 2.88M 2.63M 332M 5.03M 34.84M 13.64M 173M 13.13M 12.85M 553M 4.2M 2.97M 2.65M 2.45M 2.23M 282M 4.26M 29.56M 11.57M 147M 11.15M 10.91M 469M
Net income -4.04M -2.86M -2.55M -2.36M -2.15M -272M -4.11M -28.48M -11.15M -142M -10.74M -10.51M -452M -6.1M -4.32M -3.85M -3.56M -3.24M -410M -6.2M -43M -16.83M -214M -16.21M -15.86M -682M
Net Debt -10.87M -7.69M -6.86M -6.34M -5.77M -731M -11.05M -76.58M -29.98M -381M -28.87M -28.25M -1.21B -8.23M -5.83M -5.19M -4.8M -4.37M -553M -8.37M -58.01M -22.71M -289M -21.87M -21.4M -920M
Projected Income Statement - Annual - Rhelion Life Sciences Corp.
Logo Rhelion Life Sciences Corp.
Rhelion Life Sciences Corp., formerly Red Light Holland Corp., is a science and research led company advancing the natural psychedelic drug discovery and development sector. Through its wholly owned subsidiary Filament Health Corp., the Company is developing naturally derived psilocybin drug candidates, including its patented PEX010, and supporting clinical research and compassionate use programs with institutions around the world. PEX010 is its standardized natural psilocybin drug candidate, studied across 80+ clinical trials worldwide, including FDA-authorized programs in depression, PTSD, cancer-related distress, and substance use disorders. Its products also include IBEXX and MB2500. IBEXX is its botanical ibogaine drug candidate. MB2500 is its whole-leaf coca extract drug candidate. It also operates in the Netherlands' legal adult-use market and supports voluntary data collection and research to help advance the scientific understanding of natural psychedelics.
Employees
-
Date Price Change Volume
26-10-16 $0.0250 0.00% 171,070
26-10-15 $0.0250 0.00% 106,660
26-10-14 $0.0250 0.00% 111,544
26-10-13 $0.0250 0.00% 54,553
  1. Stock Market
  2. Stocks
  3. RHEL Stock